Motor fluctuations and Helicobacter pylori in Parkinson's disease

Journal of Neurology

Volumn 260, Issue 12, 2013, Pages 2974-2980

  Rahne, Karl Erik ^a   Tagesson, Carl ^b   Nyholm, Dag ^b  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Helicobacter pylori; Levodopa; Motor fluctuations; Parkinson's disease; Sleep

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARKINSON DISEASE; PRIORITY JOURNAL; SCREENING TEST; SLEEP DISORDER; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; UREA BREATH TEST; VITAMIN BLOOD LEVEL; WEARING OFF QUESTIONNAIRE 9;

AGED; ANTIPARKINSON AGENTS; BREATH TESTS; FEMALE; FOLIC ACID; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL ABSORPTION; LEVODOPA; MALE; PARKINSON DISEASE; TREATMENT OUTCOME; VITAMIN B 12;

EID: 84890787955     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7089-6     Document Type: Article

References (46)

1. Lewitt PA (2008) Levodopa for the treatment of Parkinson's disease. N Engl J Med 359(23):2468-2476. doi: 10.1056/NEJMct0800326
2. Nyholm D, Lennernas H (2008) Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 4(2):193-203. doi: 10.1517/17425255.4.2.193
3. Nyholm D, Karlsson E, Lundberg M, Askmark H (2010) Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. Eur J Neurol 17(2):260-266. doi: 10.1111/j.1468-1331.2009.02866.x
4. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A (2006) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66(12):1824-1829. doi: 10.1212/01.wnl.0000221672.01272.ba
5. Niehues M, Hensel A (2009) In-vitro interaction of l-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinical differences in bioavailability? J Pharm Pharmacol 61(10):1303-1307. doi: 10.1211/jpp/61.10.0005
6. Fiddian-Green RG (2007) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 68(13):1085. doi: 10.1212/01.wnl.0000260440.07107.99 author reply 1085
7. Lyte M (2010) Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori. Med Hypotheses 74(5):895-897. doi: 10.1016/j.mehy.2009.11.001
8. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B (2012) Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 19(6):864-869. doi: 10.1111/j.1468-1331.2011.03643.x
9. Lacy BE, Rosemore J (2001) Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr 131(10):2789S-2793S
10. Brown LM (2000) Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22(2):283-297
11. Pounder RE, Ng D (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9(Suppl 2):33-39
12. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agreus L (2008) Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 43(12):1448-1455. doi: 10.1080/00365520802273025
13. Graham DY, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans DJ Jr, Malaty HM, Evans DG (1991) Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 36(8):1084-1088
14. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM (1992) Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 116(9):705-708
15. Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19(3):449-490. doi: 10.1128/CMR.00054-05
16. Lehours P, Yilmaz O (2007) Epidemiology of Helicobacter pylori infection. Helicobacter 12(Suppl 1):1-3. doi: 10.1111/j.1523-5378.2007.00541.x
17. Malaty HM (2007) Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 21(2):205-214. doi: 10.1016/j.bpg.2006.10.005
18. Xia HH, Talley NJ (1997) Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications. Am J Gastroenterol 92(10):1780-1787
19. Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM (1997) Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 92(9):1480-1482
20. Haruma K, Okamoto S, Kawaguchi H, Gotoh T, Kamada T, Yoshihara M, Sumii K, Kajiyama G (1997) Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol 25(4):583-586
21. Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV (1992) Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 102(1):41-46 [pii]:S0016508592000362
22. Telaranta-Keerie A, Kara R, Paloheimo L, Harkonen M, Sipponen P (2010) Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol 45(9):1036-1041. doi: 10.3109/00365521.2010.487918
23. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev (11):CD008453. doi: 10.1002/14651858.CD008453.pub2
24. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427-442
25. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738-750. doi: 10.1002/mds.10473
26. Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X (2008) The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14(3):205-212. doi: 10.1016/j.parkreldis.2007.07.013
27. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25(15):2649-2653. doi: 10.1002/mds.23429
28. Evrengul H, Tanriverdi H, Kuru O, Enli Y, Yuksel D, Kilic A, Kaftan A, Kirac S, Kilic M (2007) Elevated homocysteine levels in patients with slow coronary flow: relationship with Helicobacter pylori infection. Helicobacter 12(4):298-305. doi: 10.1111/j.1523-5378.2007.00505.x
29. Hu XW, Qin SM, Li D, Hu LF, Liu CF (2013) Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta Neurol Scand 128(2):73-82. doi: 10.1111/ane.12106
30. Pietroiusti A, Galante A, Magrini A, Bergamaschi A (2008) Helicobacter pylori interference with micronutrients and orally administered drugs: a new mechanism explaining its role in extragastric disorders. Mini Rev Med Chem 8(2):135-141
31. Marino MC, de Oliveira CA, Rocha AM, Rocha GA, Clementino NC, Antunes LF, Oliveira RA, Martins AS, Del Puerto HL, D'Almeida V, Galdieri L, Pedroso ER, Cabral MM, Nogueira AM, Queiroz DM (2007) Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency. Gut 56(4):469-474. doi: 10.1136/gut.2006.095125
32. Sekhon J (2011) Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 42:1-52
33. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351(24):2498-2508. doi: 10.1056/NEJMoa033447
34. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18-27. doi: 10.1002/ana.22060
35. Nyholm D, Askmark H, Aquilonius SM (2011) Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint. Ann Neurol 69(2):424. doi: 10.1002/ana.22257 author reply 425
36. Wong WM, Lam SK, Lai KC, Chu KM, Xia HH, Wong KW, Cheung KL, Lin SK, Wong BC (2003) A rapid-release 50-mg tablet-based 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 17(2):253-257 [pii]:1417
37. Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, Virtamo J, Haapiainen R, Rautelin H (2003) Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 111(6):619-624
38. Salomaa-Rasanen A, Kosunen TU, Mattila J, Sarna S, Rautelin H (2004) Age-dependent accuracy of Helicobacter pylori antibody assays for adults, with special emphasis on atrophic gastritis. Clin Diagn Lab Immunol 11(6):1185-1188. doi: 10.1128/CDLI.11.6.1185-1188.2004
39. Graham DY, Opekun AR, Yamaoka Y, Osato MS, el-Zimaity HM (2003) Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 17(2):193-200
40. Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Kagawa J (2003) Influence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol 38(10):937-941. doi: 10.1007/s00535-003-1176-x
41. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Harkonen M (2000) Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol 35(9):950-956
42. Drake IM, Mapstone NP, Schorah CJ, White KL, Chalmers DM, Dixon MF, Axon AT (1998) Reactive oxygen species activity and lipid peroxidation in Helicobacter pylori associated gastritis: relation to gastric mucosal ascorbic acid concentrations and effect of H pylori eradication. Gut 42(6):768-771
43. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL (2008) Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 23(12):1696-1700. doi: 10.1002/mds.22190
44. Salim AS (1993) The relationship between Helicobacter pylori and oxygen-derived free radicals in the mechanism of duodenal ulceration. Intern Med 32(5):359-364
45. Lahner E, Annibale B, Delle Fave G (2009) Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 29(4):379-386. doi: 10.1111/j.1365-2036.2008.03906.x
46. Dixon M (1996) Pathological consequences of Helicobacter pylori infection. Scand J Gastroenterol Suppl 215:21